Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial

Metabolism: Clinical and Experimental

Volumn 74, Issue , 2017, Pages 43-46

  Katsiki, Niki ^a   Athyros, Vasilios G ^a   Mikhailidis, Dimitri P ^b   Mantzoros, Christos ^c  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; BOCOCIZUMAB; EVOLOCUMAB; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INCLISIRAN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE 9; SERINE PROTEINASE INHIBITOR; SIMVASTATIN; TRIACYLGLYCEROL; HYPOCHOLESTEROLEMIC AGENT; MONOCLONAL ANTIBODY; PCSK9 PROTEIN, HUMAN;

ACUTE CORONARY SYNDROME; ADVERSE OUTCOME; BRAIN HEMORRHAGE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EDITORIAL; FAMILIAL HYPERCHOLESTEROLEMIA; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTCOMES RESEARCH; PATIENT SAFETY; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTEINASE INHIBITION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SIDE EFFECT; TARGET ORGAN; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASE; METABOLISM; PATHOPHYSIOLOGY; RISK;

ANTIBODIES, MONOCLONAL; ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; HUMANS; HYPERCHOLESTEROLEMIA; PROPROTEIN CONVERTASE 9; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK; SERINE PROTEINASE INHIBITORS;

EID: 85018990636     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2017.04.007     Document Type: Editorial

References (32)

1. Chaudhary, R., Garg, J., Shah, N., Sumner, A., PCSK9 inhibitors: a new era of lipid lowering therapy. World J Cardiol 9:2 (2017), 76–91.
2. Paton, D.M., PCSK9 inhibitors: monoclonal antibodies for the treatment of hypercholesterolemia. Drugs Today (Barc) 52:3 (2016), 183–192.
3. Blom, D.J., Dent, R., Castro, R.C., Toth, P.P., PCSK9 inhibition in the management of hyperlipidemia: focus on evolocumab. Vasc Health Risk Manag 12 (2016), 185–197.
4. Khan, A.R., Bavishi, C., Riaz, H., Farid, T.A., Khan, S., Atlas, M., et al. Increased risk of adverse neurocognitive outcomes with proprotein convertase subtilisin-kexin type 9 inhibitors. Circ Cardiovasc Qual Outcomes, 10(1), 2017.
5. Robinson, J.G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., et al., ODYSSEY LONG TERM Investigators, Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 372:16 (2015), 1489–1499.
6. Sabatine, M.S., Giugliano, R.P., Wiviott, S.D., Raal, F.J., Blom, D.J., Robinson, J., et al., Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators, Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 372:16 (2015), 1500–1509.
7. Ridker, P.M., Tardif, J.C., Amarenco, P., Duggan, W., Glynn, R.J., Jukema, J.W., et al., SPIRE Investigators, Lipid-reduction variability and antidrug-antibody formation with Bococizumab. N Engl J Med 376:16 (2017), 1517–1526.
8. Roth, E.M., Goldberg, A.C., Catapano, A.L., Torri, A., Yancopoulos, G.D., Stahl, N., et al. Antidrug antibodies in patients treated with Alirocumab. N Engl J Med 376:16 (2017), 1589–1590.
9. Sabatine, M.S., Giugliano, R.P., Keech, A.C., Honarpour, N., Wiviott, S.D., Murphy, S.A., et al., FOURIER Steering Committee and Investigators, Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med, 2017 [Epub ahead of print].
10. Schwartz, G.G., Bessac, L., Berdan, L.G., Bhatt, D.L., Bittner, V., Diaz, R., et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J 168:5 (2014), 682–689.
11. Nicholls, S.J., Puri, R., Anderson, T., Ballantyne, C.M., Cho, L., Kastelein, J.J., et al. Effect of Evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. JAMA 316:22 (2016), 2373–2384.
12. Catapano, A.L., Graham, I., De Backer, G., Wiklund, O., Chapman, M.J., Drexel, H., et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European atherosclerosis Society (EAS) developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 253 (2016), 281–344.
13. Athyros, V.G., Mikhailidis, D.P., Pharmacotherapy: statins and new-onset diabetes mellitus–a matter for debate. Nat Rev Endocrinol 8:3 (2012), 133–134.
14. Banach, M., Rizzo, M., Toth, P.P., Farnier, M., Davidson, M.H., Al-Rasadi, K., et al. Statin intolerance - an attempt at a unified definition. Position paper from an international lipid Expert Panel. Arch Med Sci 11:1 (2015), 1–23.
15. Brault, M., Ray, J., Gomez, Y.H., Mantzoros, C.S., Daskalopoulou, S.S., Statin treatment and new-onset diabetes: a review of proposed mechanisms. Metabolism 63:6 (2014), 735–745.
16. Stroes, E.S., Thompson, P.D., Corsini, A., Vladutiu, G.D., Raal, F.J., Ray, K.K., et al., European Atherosclerosis Society Consensus Panel, Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel statement on assessment, aetiology and management. Eur Heart J 36:17 (2015), 1012–1022.
17. Katsiki, N., Rizzo, M., Mikhailidis, D.P., Mantzoros, C.S., New-onset diabetes and statins: throw the bath water out, but, please, keep the baby!. Metabolism 64:4 (2015), 471–475.
18. Schmidt, A.F., Swerdlow, D.I., Holmes, M.V., Patel, R.S., Fairhurst-Hunter, Z., Lyall, D.M., et al. PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol 5:2 (2017), 97–105.
19. Lotta, L.A., Sharp, S.J., Burgess, S., Perry, J.R., Stewart, I.D., Willems, S.M., et al. Association between low-density lipoprotein cholesterol-lowering genetic variants and risk of type 2 diabetes: a meta-analysis. JAMA 316:13 (2016), 1383–1391.
20. Katsiki, N., Athyros, V.G., Karagiannis, A., Exploring the Management of Statin Intolerant Patients: 2016 and beyond. Curr Vasc Pharmacol 14:6 (2016), 523–533.
21. Giugliano, R.P., Mach, F., Zavitz, K., Kurtz, C., Schneider, J., Wang, H., et al., EBBINGHAUS Investigators, Design and rationale of the EBBINGHAUS trial: a phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-a cognitive study of patients enrolled in the FOURIER trial. Clin Cardiol 40:2 (2017), 59–65.
22. http://www.ajmc.com/conferences/acc-2017/dr-robert-p-giugliano-on-the-results-of-the-ebbinghaus-evolocumab-cognitive-study [Last accessed 28 March 2017].
23. Ridker, P.M., Revkin, J., Amarenco, P., Brunell, R., Curto, M., Civeira, F., et al., SPIRE Cardiovascular Outcome Investigators, Cardiovascular efficacy and safety of Bococizumab in high-risk patients. N Engl J Med 376:16 (2017), 1527–1539.
24. Ray, K.K., Landmesser, U., Leiter, L.A., Kallend, D., Dufour, R., Karakas, M., et al. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N Engl J Med 376:15 (2017), 1430–1440.
25. Cannon, C.P., Blazing, M.A., Giugliano, R.P., McCagg, A., White, J.A., Theroux, P., et al., IMPROVE-IT Investigators, Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 372:25 (2015), 2387–2397.
26. American Diabetes Association, Cardiovascular disease and risk management. Sec. 9. In standards of medical Care in Diabetes 2017. Diabetes Care 40:Suppl. 1 (2017), S75–S87.
27. Jellinger, P.S., Handelsman, Y., Rosenblit, P.D., Bloomgarden, Z.T., Fonseca, V.A., Garber, A.J., et al. American Association of Clinical Endocrinologists and American College of endocrinology guidelines for management of dyslipidemia and prevention of atherosclerosis. Endocr Pract 23:Suppl 2 (2017), 1–87.
28. Dullaart, R.P., PCSK9 inhibition to reduce cardiovascular events. N Engl J Med, 2017 [Epub ahead of print].
29. Waite, L.H., Phan, Y.L., Spinler, S.A., What's next for dyslipidemia management? The 2013 ACC/AHA guidelines, the NLA recommendations, and beyond. J Am Pharm Assoc (2003) 56:3 (2016), 284–292.
30. Writing Committee, Lloyd-Jones, D.M., Morris, P.B., Ballantyne, C.M., Birtcher, K.K., Daly, D.D. Jr., et al. 2016 ACC Expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on clinical expert consensus documents. J Am Coll Cardiol 68:1 (2016), 92–125.
31. Landmesser, U., John Chapman, M., Farnier, M., Gencer, B., Gielen, S., Hovingh, G.K., et al., European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS), European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. Eur Heart J, 2016 [pii: ehw480. Epub ahead of print].
32. http://pace-cme.org/2017/03/16/consistent-long-term-ldl-c-reduction-by-pcsk9-inhibitor-translates-into-cv-benefit-in-high-risk-patients-already-on-statins/ [Last accessed 28 March 2017].